Telum Therapeutics, a Navarre, Spain-based biotech developing engineered protein-based antimicrobials against multidrug-resistant bacteria, has raised €18 million in Series A funding led by the AMR Action Fund. The company uses its APEX® platform to combine metagenomic datasets, generative AI, and synthetic biology to create novel Engineered Phage Lytic Enzymes (EPLEs) targeting pathogens like Acinetobacter baumannii in hospital-acquired bacterial pneumonia. The capital will advance its lead program into Phase 1 clinical trials.
AMR Action Fund Validates Enzybiotic Approach
The timing aligns with renewed institutional interest in antimicrobial resistance solutions. Micreos raised multiple rounds totaling over €87 million between 2019 and 2022, while Locus Biosciences secured over $105 million including a $23.9 million BARDA award in 2024. Telum's focus on purified enzyme proteins rather than live phages addresses manufacturing and regulatory hurdles that competitors face.
Rising Resistance Threatens Hospital Care
Acinetobacter baumannii ranks as a WHO Priority 1 Critical pathogen with few remaining treatment options for hospitalized patients. Global AMR deaths reached 1.27 million in 2019 and are projected to exceed 39 million by 2050. Traditional antibiotic pipelines have largely stalled as large pharmaceutical companies exited the space.
APEX Platform Engineers Beyond Nature
Telum's APEX® system scans environmental metagenomes to identify lytic enzyme modules, then applies generative AI to design synthetic consensus proteins that outperform natural variants in stability and spectrum. This protein modality avoids the complexities of live phage therapies pursued by companies like BiomX and Armata Pharmaceuticals.
As Dr. Subhendu Basu, CEO of Telum, noted:
"This financing provides a clear path to complete Phase 1 development of our lead program targeting Acinetobacter baumannii HABP/VABP."
AMR Action Fund Backs Clinical Transition
The AMR Action Fund, the world's largest VC dedicated exclusively to antimicrobial innovation, led the round with participation from Inveready and existing investors including Invivo Partners and CDTI-Innvierte. The fund's involvement signals strategic validation from major pharmaceutical backers seeking new modalities after exiting traditional antibiotic discovery.
Phage Therapy Market Expands Steadily
The phage therapy market stands at $1.29 billion in 2026 and is projected to reach $1.54 billion by 2031. The broader antibiotic resistance market is expected to grow from $9.7 billion in 2025 to $14.3 billion by 2033. Capital continues flowing into enzybiotic approaches that offer lower resistance risk and clearer regulatory paths than live bacteriophages.
Competitors such as BiomX raised $50 million alongside its 2024 acquisition of Adaptive Phage Therapeutics, while Armata Pharmaceuticals secured a $35 million loan in 2024. Lysando AG pursues similar engineered proteins but focuses on topical applications rather than systemic hospital use.